ArticleCureus2026
HNF1A-Maturity-Onset Diabetes of the Young (MODY) in a Family With a Rare Silent Variant: Clinical Challenges and Variable Expressivity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes characterized by autosomal dominant inheritance, typically occurring during adolescence or early adulthood. Mutations in the hepatocyte nuclear factor 1-α (HNF1A) gene are among the most common causes of MODY and are frequently misdiagnosed as type 1 (T1D) or type 2 diabetes (T2D), leading to inappropriate management. We report the case of a preschool-aged boy who presented with polyuria and polydipsia, fasting hyperglycemia, negative pancreatic autoantibodies, and an elevated C-peptide level. A multi-generational family history of diabetes was noted, and his older sister was previously diagnosed with T2D. Genetic testing using direct sequencing identified a rare heterozygous silent variant in exon 8 of the HNF1A gene (c.1533G>A; p. Gln511=) in the index patient, his sister, and his mother. To date, the mother remains entirely asymptomatic and normoglycemic. The variant is exceptionally rare in global population databases. Both siblings have maintained optimal glycemic control for four years through dietary modification alone, without requiring pharmacological therapy. This case demonstrates that rare silent HNF1A variants can be clinically pathogenic, likely by disrupting pre-mRNA splicing kinetics or mRNA stability. The observed familial segregation strongly suggests a clinical pattern of incomplete penetrance (an asymptomatic maternal carrier) and variable expressivity, potentially pointing to an attenuated, partial genetic defect rather than a complete loss of function. This case underscores the importance of integrating rigorous clinical phenotyping and familial segregation tracking alongside automated in silico predictions when evaluating synonymous variants in suspected monogenic diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.